


RealRate

PHARMACEUTICAL 2020

Forty Seven Inc. Rank 84 of 362





PHARMACEUTICAL 2020



Forty Seven Inc. Rank 84 of 362

The relative strengths and weaknesses of Forty Seven Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Forty Seven Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 276% points. The greatest weakness of Forty Seven Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 66% points.

The company's Economic Capital Ratio, given in the ranking table, is -3.1%, being 300% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	337,524
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	22,795
Liabilities, Non-Current	844
Other Assets	4,846
Other Compr. Net Income	174
Other Expenses	2,554
Other Liabilities	2,026
Other Net Income	0
Property and Equipment	1,223
Research and Development	83,792
Revenues	19,143
Selling, General and Administrative Expense	20,418

Output Variable	Value in 1000 USD
Assets	343,593
Liabilities	25,665
Expenses	106,764
Stockholders Equity	317,928
Net Income	-87,621
Comprehensive Net Income	-87,534
Economic Capital Ratio	-3.1%